TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Traws Pharma ( (TRAW) ) has shared an announcement.
On November 21, 2025, Traws Pharma held its Annual Meeting virtually, with 48% of its outstanding shares represented. During the meeting, stockholders elected seven directors, approved amendments to the 2021 Incentive Compensation Plan, and ratified KPMG LLP as the independent auditor for 2025. Additionally, it was decided that advisory votes on executive compensation will occur every two years, with the next vote scheduled for the 2027 Annual Meeting.
Spark’s Take on TRAW Stock
According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.
Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.
To see Spark’s full report on TRAW stock, click here.
More about Traws Pharma
Average Trading Volume: 310,754
Technical Sentiment Signal: Sell
Current Market Cap: $20.46M
See more data about TRAW stock on TipRanks’ Stock Analysis page.